Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $793.81 Average Price Target from Brokerages

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been assigned an average rating of “Moderate Buy” from the twenty-five analysts that are presently covering the company, MarketBeat.com reports. Nine analysts have rated the stock with a hold recommendation, fourteen have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $793.8095.

A number of brokerages have issued reports on REGN. Truist Financial reduced their price target on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Wells Fargo & Company upped their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Royal Bank Of Canada boosted their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 29th. Finally, Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a report on Monday, February 9th.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $787.04 on Tuesday. The company has a 50-day moving average price of $769.67 and a two-hundred day moving average price of $676.28. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $821.11. The stock has a market cap of $83.21 billion, a price-to-earnings ratio of 18.94, a price-to-earnings-growth ratio of 2.09 and a beta of 0.40. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm posted $12.07 earnings per share. The business’s revenue was up 2.5% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is 9.05%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 5,274 shares of company stock worth $4,142,738 over the last 90 days. 7.02% of the stock is currently owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Osaic Holdings Inc. raised its holdings in Regeneron Pharmaceuticals by 55.2% during the 2nd quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock worth $9,607,000 after purchasing an additional 6,073 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its stake in shares of Regeneron Pharmaceuticals by 153.4% during the third quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after buying an additional 73,176 shares during the last quarter. PGGM Investments raised its stake in shares of Regeneron Pharmaceuticals by 9.7% during the third quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock worth $52,057,000 after buying an additional 8,187 shares during the last quarter. Rakuten Investment Management Inc. acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at approximately $33,121,000. Finally, Sound Shore Management Inc CT bought a new position in Regeneron Pharmaceuticals in the third quarter valued at approximately $64,677,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.